ES
MARKETS / NASDAQ / AMLX
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Amylyx Pharmaceuticals, Inc. AMLX

5 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-1.53
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-61.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 5-year series below
Revenue Net income
0.10.20.30.40.0-0.1202120242025
0.10.20.30.40.0-0.1202120242025

Per share
USD -1.53
Diluted EPS, FY2025
EPS
0.40.81.2-1.53202120242025
0.40.81.2-1.53202120242025

The company pays no cash dividend.

Profitability
-61.6%
Return on equity, FY2025
ROE
481216-61.6%202120242025
481216-61.6%202120242025
Operating margin—
Net margin—
Return on assets-55.0%

Each USD of equity lost 62 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.11B
Shares outstanding, FY2025
0.010.11202120242025
0.010.11202120242025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 332.6M
total assets, end of FY2025
Total assetsUSD 332.6M
EquityUSD 305.3M
CashUSD 226.7M
Current ratio14.27×

Equity funds 92% of total assets.

History
5 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
Revenue $B
0.0
0.1
0.4
0.0
0.0
Operating income $B
−0.2
−0.3
0.0
−0.2
−0.1
EBITDA $B
−0.2
−0.3
0.0
−0.2
−0.1
Income tax $B
0.0
−0.0
0.0
0.0
·
Net income $B
−0.1
−0.3
0.0
−0.2
−0.1
EPS, diluted $
−1.53
−4.43
0.70
−3.39
−13.35
Dividend / sh $
·
·
·
·
·
Payout %
·
·
·
·
·
ROE %
−61.6
−100.9
12.7
−209.4
·
Shares out B
0.11
0.07
0.07
0.07
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
15 of 15
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed